Breast cancer
Conditions
Brief summary
The genomic tumor architecture as described by CAAI, and tumor cell heterogeneity before and after treatment as detected and verified by DNA analysis (SNP analysis/sequencing) and quantified by the six CARMA indices.
Detailed description
The overall change in the expression (the number and the magnitude of change) of mRNA, and protein in the different treatment groups across timepoints., Changes in the metabolite distribution (individual metabolites and magnitude) as measured by HR-MAS in the different treatment groups., Treatment induced changes and characteristics in circulating tumor DNA and circulating tumor cells in peripheral blood compared to tumor response, Difference in levels of fatigue between treatment arms., Host-related, tumor-related and treatment-related factors predicting chronic fatigue
Interventions
DRUGsolution à diluer pour perfusion
Sponsors
Oslo University Hospital HF
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The genomic tumor architecture as described by CAAI, and tumor cell heterogeneity before and after treatment as detected and verified by DNA analysis (SNP analysis/sequencing) and quantified by the six CARMA indices. | — |
Secondary
| Measure | Time frame |
|---|---|
| The overall change in the expression (the number and the magnitude of change) of mRNA, and protein in the different treatment groups across timepoints., Changes in the metabolite distribution (individual metabolites and magnitude) as measured by HR-MAS in the different treatment groups., Treatment induced changes and characteristics in circulating tumor DNA and circulating tumor cells in peripheral blood compared to tumor response, Difference in levels of fatigue between treatment arms., Host-related, tumor-related and treatment-related factors predicting chronic fatigue | — |
Countries
Norway
Outcome results
None listed